BackAvalo Therapeutics Overview
Avalo Therapeutics Inc

Avalo Therapeutics Target Price

See Avalo Therapeutics's analyst price targets ($44) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$19.23

Average Target Price

$43.50126.2% upside

8 analysts in the last 4 months

High: $60 | Low: $30

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Guggenheim$48149.6% upsideOpen
2026-08-07H.C. Wainwright$3056% upsideOpen
2026-07-06Leerink Partners$3897.6% upsideOpen
2026-05-14Wedbush$3476.8% upsideOpen
2026-05-14Mizuho Securities$45134% upsideOpen
2026-05-14H.C. Wainwright$3582% upsideOpen
2026-05-11Piper Sandler$60212% upsideOpen
2026-05-06BTIG$58201.6% upsideOpen
2026-04-08Wolfe Research$48149.6% upsideOpen
2026-02-02Guggenheim$50160% upsideOpen
2025-12-17Mizuho SecuritiesJoseph Catanzaro$39102.8% upsideOpen
2025-09-17H.C. Wainwright$2530% upsideOpen
2025-03-25JefferiesKambiz Yazdi$2319.6% upsideOpen
2024-04-16OppenheimerLeland Gershell$3582% upsideOpen

Avalo Therapeutics (AVTX) FAQ

As of the most recent data, AVTX shows a target price of $44. Scroll down for historical charts and peer comparison views.

If Avalo Therapeutics moved to the average analyst target of $44, shares would be roughly 126.2% higher than $19.23. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Avalo Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Avalo Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $44) with ownership activity and broader fundamentals.

Avalo Therapeutics's target price is $44; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.